Johnson & Johnson (NYSE:JNJ) marched up 15.79% compared to a 52-week low price of $121. The shares were last seen trading -0.78% lower, taking the closing price at $140.11 on 7/11/2019. At a recent session, the prices were hovering between $139.02 and $141.21. This company shares are 6.47% off its target price of $149.17 and the current market capitalization stands at $375.77B. The recent change has given its price a 0.73% lead over SMA 50 and -5.96% deficit over its 52-week high. The stock witnessed 0.24% gains, 3.34% gains and 8.67% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JNJ’s volatility during a week at 1.14% and during a month it has been found around 1.19%.

What Does Johnson & Johnson (JNJ) Do?

The company describes itself in regulatory filings as, “Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.” [Text can be found here: https://www.marketwatch.com/investing/stock/JNJ/profile under company description.]

Johnson & Johnson (JNJ) Top Holders

Institutional investors currently hold around $254.92 billion or 69.5% in JNJ stock. Look at its top three institutional owners: Vanguard Group Inc owns $31.56 billion in Johnson & Johnson, which represents roughly 8.4% of the company’s market cap and approximately 12.38% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 188,893,693 shares of the stock are valued at $26.67 billion. The third largest holder is State Street Corp, which currently holds $21.91 billion worth of this stock and that ownership represents nearly 5.83% of its market capitalization.

Johnson & Johnson 13F Filings

At the end of March reporting period, 1,211 institutional holders increased their position in Johnson & Johnson (NYSE:JNJ) by some 61,188,618 shares, 1,376 decreased positions by 63,656,716 and 261 held positions by 1,680,000,000. That puts total institutional holdings at 1,805,000,000 shares, according to SEC filings. The stock grabbed 120 new institutional investments totaling 4,291,282 shares while 102 institutional investors sold out their entire positions totaling 4,897,594 shares.

Johnson & Johnson (NYSE:JNJ) Insider Trades

Multiple company employees have indulged in significant insider trading. Johnson & Johnson disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director HEWSON MARILLYN A has acquired 3,000 shares of Johnson & Johnson (JNJ) in the trading session dated Jun. 11, 2019. These shares are worth $419,040 and were traded at $139.68 each. The SEC filing shows that PRINCE CHARLES performed a purchase of 2,000 shares. The Director added these shares by way of transaction on Dec. 14, 2018. The company’s shares were assimilated at $134.37 per share worth to an investment of some $268,740 to the account of PRINCE CHARLES.

Director, PEREZ WILLIAM D, purchased 1,000 common shares of Johnson & Johnson (JNJ) in the open market. In a transaction dated Dec. 14, 2018, the shares were bought at an average price of $133.91, giving away a sum of $133,910. After this purchase, 18,222 common shares of JNJ are directly owned by the insider, with total stake valued at $2,553,084.

In the transaction dated Dec. 14, 2018, a great number of shares acquired came courtesy the Director; MULCAHY ANNE M added a total of 748 shares at an average price of $133.76, amounting to approximately $100,052. The insider now directly owns 6,537 shares worth $915,899.

Johnson & Johnson (JNJ) Analyst Guide

Several analysts have released their opinion on Johnson & Johnson (NYSE:JNJ), with 5 analysts believing it is a strong buy. Whereas 8 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.32 average brokerage recommendation [T1].